Women in midlife are increasingly likely to be on a cocktail of GLP-1, microdose psilocybin, and cannabis gummies. But does this combo result in effects as potent as a mocktail?
Midlife women are the most prescribed demographic for GLP-1 medications — Ozempic, Wegovy, Mounjaro — of any group in the United States. And we are also the fastest-growing demographic in psychedelic spaces. microdosing circles. cannabis wellness. With 8.5 million Americans having tried microdosing in the last year alone, and women over 60 as the fastest-growing cannabis consumer segment, the overlap isn’t hypothetical. It’s already happening. in your medicine cabinet. in your body. without nearly enough information to guide you.
So I went looking for the 411.
What I found wasn’t just a drug interaction story. It was a convergence story. Two categories of medicine arriving at strikingly similar places: quieting the relentless mental noise around food. softening compulsive cravings. shifting the relationship between self and substance. Modern pharmaceuticals and ancient natural remedies are landing in midlife women’s bodies at a historically unprecedented rate.
What you’ll learn in this post:
Why midlife women are the single demographic most likely to be on a GLP-1 medication right now — and why that matters if you’re also exploring psychedelics or cannabis
What actually happens in your body when GLP-1 drugs and psilocybin (or edibles) interact
The striking biological overlap between what GLP-1s and psilocybin are both trying to do
Why “food noise” and ruminating thoughts may be two expressions of the same underlying pattern — and why both of these medicines are being studied for it
The three areas where midlife women stand to gain the most — and where the research gaps are most dangerous
What to actually do if you’re navigating all of this right now
I think one of the things I loved the most about this gathering is how organic and natural it felt. I imagine that every one of these events would feel slightly different, and that is part of what is magical about what you are creating.
Thank you for this fascinating introduction to wonderful women.
The evening was memorable and meaningful. I had never tried psilocybin. I knew my “first time” had to be in a managed environment with an experienced facilitator. You absolutely provided that experience, so thank you!
Thank you so much for creating this beautiful healing space for women.
Next gathering: May 9
MONTHLY MEMBER CALL ‼️ THIS MONDAY 4/20 at 5:30pm PT
Paid Subscribers are invited to join others navigating psychedelics for the monthly SetSet Member call. Attendees can expect support for integration, microdosing, sourcing, and more. RSVP to hi@getsetset.com
Last year, the RAND American Life Panel surveyed more than 13,000 U.S. adults about GLP-1 use. Women aged 50 to 64 had the highest usage of any group — 20 percent reporting current or past GLP-1 use. Women aged 30 to 49 were more than twice as likely as men the same age to report having used one.
Women are the largest users, yet we’ve been almost entirely left out of the research.
RAND put it plainly: despite widespread use of GLP-1s by perimenopausal women, this population has been largely ignored in studies of the drugs’ risks and benefits. Women and their providers are making decisions with incomplete information during one of the most physiologically and psychosocially challenging transitions of their lives.
I’ve watched this pattern play out for a decade — first in cannabis, now in psychedelics. Women lead adoption. Women carry risk. Women are studied last. And now it’s happening again with GLP-1s; compounding is already a tenuous standard of care around emerging interventions.
GLP-1 agonists quiet what users call “food noise” — the relentless, intrusive mental chatter about food and cravings that is less about hunger and more about compulsion. They do this partly by modulating the brain’s dopamine reward circuitry.
Psilocybin, acting on serotonin 5-HT2A receptors, quiets another kind of relentless mental noise: ruminating thoughts. obsessive loops. compulsive returns to old patterns.
These are not the same thing, but they rhyme.
Serotonin and GLP-1 work together in the gut to regulate feeding behavior. A 2025 mouse study combining semaglutide and psilocybin outperformed either drug alone in reducing weight and liver steatosis. A separate preclinical study found that psilocybin normalized the GIP hormone — the exact mechanism behind tirzepatide, currently the most potent weight loss drug available.
Researchers are beginning to see these medicines as potentially complementary, so midlife women who combine them, intentionally or not, are running an experiment no one designed.
GLP-1 agonists dramatically slow gastric emptying — a feature that keeps you full longer, but creates a serious problem for orally ingested medicines.
Psilocybin is a prodrug. It isn’t active until converted into psilocin in your gut and liver. Most people feel the effects 45 to 90 minutes after ingesting mushrooms. On a GLP-1, that timeline breaks down.
Retreat clinicians are now documenting a consistent pattern: very long onset times, muted effects, unpredictable experience quality — even at increased doses. Some clients feel nothing for 75 to 90 minutes, then get an abrupt, intense experience at an unexpected moment. Others get almost nothing at all.
This affects informed consent, dosing, and a facilitator’s ability to prepare you for what’s coming. One proposed workaround: sublingual psilocin, which bypasses the gut entirely and enters circulation directly.
The same delayed absorption applies to MDMA and ketamine taken orally — both timing-sensitive substances where predictability matters.
THC stimulates appetite through CB1 receptor activation. GLP-1 suppresses it through dopamine and gut signaling. No formal pharmacokinetic interaction exists, but while they don’t block each other’s absorption, the pharmacodynamic opposition is real. If you’re using a GLP-1 for metabolic reasons, regular cannabis use may be quietly undermining it.
Edibles are also subject to delayed gastric emptying: later onset, longer and less predictable duration. If your usual dose has been behaving strangely, this may be why.
At high doses, both GLP-1s and cannabis slow gut motility — raising theoretical risk of compounding nausea and GI distress, and separate concerns around anesthesia safety before surgery.
The counterintuitive finding: GLP-1s appear to reduce Cannabis Use Disorder risk. A cohort study of 83,000+ patients found that semaglutide was associated with a ~50% reduction in new and recurrent CUD diagnoses. The same dopamine modulation that quiets food noise is applied to substance craving.
Not medical advice. But what I’d want someone to tell me:
On a GLP-1 + planning a psilocybin experience: Tell your facilitator. Expect a significantly delayed onset. Do not redose, assuming nothing is happening. Ask about sublingual delivery.
On a GLP-1 + using cannabis: Edibles will be unpredictable — consider inhalation for more reliable timing. Know that THC and your GLP-1 are working against each other.
Microdosing + on a GLP-1: Capsule delivery is still oral, still affected. Subperceptual doses may become more subperceptual. Track it.
Ask your providers. If you feel comfortable, share your curiosity and concerns with your medical provider.
Psychedelics and Grief | Thursday, May 7, 2026Grief is one of the most universal yet isolating experiences we endure — and emerging research suggests psychedelics like psilocybin, MDMA, and 5-MeO-DMT may offer a genuine path through it. At this Salon, palliative care physician Dr. Sunil Aggarwal, who has an active petition to reschedule psilocybin at the federal level, joins grief facilitator and death doula Laura Sullivan Cassidy to explore how altered states can soften sorrow, restore meaning, and reconnect us to love after loss.
GLP-1s quiet food noise. Psilocybin quiets ruminating thoughts. and both modulate reward circuitry. both are changing how millions of women relate to craving. compulsion. the endless loop. Cannabis is helping women who’ve seen the body-transforming power of GLP-1s renew their relationship to their bodies. to intimacy. to their libido.
Women in midlife are navigating one of the most complex hormonal transitions in human biology, yet there is far too little research to support the responsible adoption of emerging drugs across categories, suppliers, and biological systems.
History continues to rhyme, but women’s health needs a new tune.
Take care,
April
Do you know someone who will love this post? 💙 Please share!
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.